Trial Profile
Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Cardiovascular disorders; HIV infections; Metabolic syndrome
- Focus Biomarker; Pharmacodynamics
- Acronyms SATURN-HIV
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 24 Jul 2017 Results of secondary analysis assessing effect of pericardial fat volume and density on markers of insulin resistance and inflammation published in the American Journal of Cardiology
- 16 Feb 2017 Results assessing effect of statin on arginine metabolites; presented at the 24th Conference on Retroviruses and Opportunistic Infections